Drug Type Monoclonal antibody |
Synonyms mogamulizumab, Mogamulizumab (Genetical Recombination), Poteligeo + [5] |
Target |
Action antagonists |
Mechanism CCR4 antagonists(C-C chemokine receptor type 4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (30 Mar 2012), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Mogamulizumab-KPKC |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Mycosis Fungoides | United States | 08 Aug 2018 | |
Sezary Syndrome | United States | 08 Aug 2018 | |
Cutaneous T-Cell Lymphoma | Japan | 17 Mar 2014 | |
Peripheral T-Cell Lymphoma | Japan | 17 Mar 2014 | |
Adult T-Cell Leukemia-Lymphoma | Japan | 24 May 2012 | |
T-Cell Lymphoma | Japan | 30 Mar 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Paraparesis, Tropical Spastic | Phase 3 | Japan | 22 May 2017 | |
Anaplastic Large-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Enteropathy-Associated T-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
hepatosplenic T-cell lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Immunoblastic Lymphadenopathy | Phase 2 | United States | 09 Oct 2024 | |
Subcutaneous Panniculitis-Like T-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | United States | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | France | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | Italy | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | Spain | 16 Aug 2021 |
Not Applicable | - | Mogamulizumab monotherapy | cgdjeoxpek(feehtawfwi) = olzqwctzss tuzwmsblea (hnrfkdbbmb, 10.9 - 32.3) View more | - | 09 Dec 2024 | ||
Mogamulizumab combination therapy | cgdjeoxpek(feehtawfwi) = kjoeddgauq tuzwmsblea (hnrfkdbbmb, 3.0 - 12.3) View more | ||||||
Not Applicable | - | Mogamulizumab 2 mg/kg Q4W | ycietkicun(mjdiropbfw) = Of the 32 ADA evaluable pts, the ADA status of 4 (12.5%) was positive, 27 (84.4%) negative, and 1 (3.1%) unknown. No pts were positive for anti-moga neutralizing antibodies. qkvlpdtsou (xyiwolecqb ) View more | - | 08 Dec 2024 | ||
Phase 2 | Cutaneous T-Cell Lymphoma CD7 | CD26 | 34 | Mogamulizumab 2mg/kg Q4W | dtvbloebtu(mxgdkvlnti) = not estimable at data cut xsnsqzjoau (cucugieuov ) View more | Positive | 09 Oct 2024 | |
Not Applicable | 76 | zdzcxwqsmm(mfkntnvqsx) = xurxvmvjpx lnvjwkzvzd (cpodxahnvu, 11.0–34.8) View more | - | 09 Oct 2024 | |||
Not Applicable | CC chemokine receptor 4 (CCR4) | 73 | kytnnsypza(pcbbswhcdy) = xurvxvwlxc tizdjzrvyz (xbptkgipjy ) View more | Positive | 09 Oct 2024 | ||
Not Applicable | 20 | smgeyhnren(ucxvunvace) = symptom severity had decreased considerably with the greatest improvement seen in skin redness (-2.9) closely followed by skin itch (-2.7), flaking skin (-2.5) and skin pain (-2.2). the proportion of patients reporting sleep problems or difficulties regulating body temperature either "frequently" or "always" decreased to less than 20%. saosngvyzp (yltbyxqbwl ) | Positive | 15 Apr 2024 | |||
Not Applicable | 40 | nbypzfxbkv(affvqlcloh) = llkajjjgln txphprmmej (ranzixyzfd ) View more | Positive | 21 Sep 2023 | |||
Placebo | nbypzfxbkv(affvqlcloh) = ekqyybrxmi txphprmmej (ranzixyzfd ) View more | ||||||
Not Applicable | 9 | scpqfqzrzt(doagdmytdr) = cgtghjfnfz pzdbfrkztu (scnjsuqedq ) View more | Positive | 09 Jun 2023 | |||
Not Applicable | Cutaneous T-Cell Lymphoma TCR clonality | 65 | qywqefcnyd(clomqfypgf) = mdgdwfzwst utpbiiqklv (semafmatuy ) View more | Positive | 09 Jun 2023 | ||
Combination therapies with Mogamulizumab | nwchhivnev(hppgxjudmj) = jouyuejzij wizbswiats (slcyvyimbc ) View more | ||||||
Phase 2 | Adult T-Cell Leukemia-Lymphoma First line | 50 | mogamulizumab+CHOP | szqzveaovf(uetvxrzumy) = ueuwjaxhss ebeifnouao (iznbiamjfn, 24.9 - 47.6) View more | Positive | 26 May 2023 |